Welcome to our dedicated page for Proqr Therapeuti SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D-heavy biotech firms like ProQR Therapeutics NV file volumes of technical data on RNA editing experiments, milestone payments and cash runway projections. If you’ve ever searched “ProQR SEC filings explained simply” after opening a 300-page annual report, you know the challenge. Stock Titan’s AI deciphers the dense science behind the Axiomer platform and connects it to the financial numbers, turning each disclosure into plain-language insights you can act on.
Our dashboard streams every submission the second it hits EDGAR, including:
- 10-Ks – a “ProQR annual report 10-K simplified” with clear R&D spend, liquidity outlook and pipeline timelines.
- 10-Qs – the “ProQR quarterly earnings report 10-Q filing” with side-by-side revenue and expense trends.
- 8-Ks – “ProQR 8-K material events explained,” from clinical trial updates to collaboration agreements.
- Form 4s – “ProQR Form 4 insider transactions real-time” so you never miss executive stock moves.
- DEF 14A – your “ProQR proxy statement executive compensation” breakdown in minutes.
Each file comes with AI-powered summaries, keyword search, and instant alerts for “ProQR insider trading Form 4 transactions.”
Want deeper context? Our “ProQR earnings report filing analysis” links R&D spikes to upcoming trial milestones, while “understanding ProQR SEC documents with AI” shows how dilution risk or royalty income flows through the statements. Track “ProQR executive stock transactions Form 4” before material announcements, compare quarter-over-quarter burn rates, and download highlighted passages for your model. With comprehensive coverage and real-time updates, Stock Titan turns every SEC document into an edge—no biotech PhD required.
ProQR Therapeutics has submitted a Clinical Trial Application (CTA) for a Phase 1 study of AX-0810, a novel drug candidate targeting NTCP (sodium taurocholate co-transporting polypeptide). This regulatory filing marks a significant milestone in the company's drug development pipeline.
Key points from the Form 6-K filing:
- The announcement was made via press release on June 26, 2025
- The filing includes a press release as Exhibit 99.1
- The information is being furnished under Form 6-K and is not considered "filed" under Section 18 of the Securities Exchange Act
- The document was signed by Dennis Hom, Chief Financial Officer
This development represents a strategic advancement in ProQR's clinical program, potentially expanding their therapeutic portfolio. The CTA submission indicates the company is progressing toward clinical trials for AX-0810, which could have implications for investors following ProQR's drug development pipeline.
FAQ
What is the current stock price of Proqr Therapeuti (PRQR)?
What is the market cap of Proqr Therapeuti (PRQR)?
What is the core focus of ProQR Therapeutics?
How does the Axiomer RNA editing platform work?
Which medical conditions does ProQR target?
How does ProQR Therapeutics generate value in its business model?
What main advantages does the Axiomer platform offer?
How does the company differentiate itself from competitors?
What role do strategic partnerships play at ProQR?
How does ProQR ensure the quality and stability of its RNA therapeutics?
